Immunpeptidomics Discovery Service

Key Service Advantages

  • High efficiency and reproducibility of immunopeptide purification
  • High quality mass spectrometry data acquisition
  • DeepNovo® algorithm-based sequencing for identifying neoantigens
  • DeepSelf immunogenicity prediction and validation
  • Stringent quality control tests and comprehensive reporting
  • Whole service return time of 3 weeks

The display of peptide antigens on cell surfaces by the major histocompatibility complex (MHC) molecules, in humans also known as the human leukocyte antigen (HLA), plays an important role in adaptive immunity through recognition by T cells. Identifying and characterising antigens displayed specifically on infected cells or tumors is a critical step for the development of immunotherapies and cancer vaccines. The standard method to do this involves purification of MHC complexes, along with the bound peptides, followed by LC-MS/MS analysis.

Our DeepImmu® Immunopeptidomics Discovery Service offers a comprehensive solution, from MHC immunopeptide purification, LC-MS/MS acquisition, DeepNovo® algorithm-based sequencing for peptide identification, sequence motif generation, binding affinity and DeepSelf immunogenicity prediction, to neoantigen screening and immunogenicity validation. This service also includes quality control tests to ensure accurate results. Our advanced software algorithms and PEAKS DeepNovo Peptidome workflow provides accurate, sensitive, and reproducible results for immunopeptide identification and quantification. All experimental parameters, quality control tests, and final results are delivered in a comprehensive report.

BSI provides DeepImmu Immunopepitdomics Discovery Services to help guide the development of effective R&D therapeutic studies and vaccines using our mass spectrometry-based technology, AI-driven DeepNovo® sequencing, and DeepSelf immunogenicity prediction tools.

Request Pricing / Schedule Consultation

PEAKS AB Contact (#22)

What we require:

  • Frozen cell pellet (>107 cells)
  • Species or cell type
  • HLA alleles (if known)

What we provide:

  • Qualitative results of immunopeptides and corresponding protein information list
  • List of all predicted immunopeptides ranked by immunogenicity scores
  • QC test results
  • Immunopeptide length distribution chart and binding affinity prediction
  • Sequence motifs for HLA alleles
  • Comprehensive report


  1. Ming Li, Ngoc Hieu Tran, Chao Peng et al. A complete mass spectrometry-based immunopeptidomics pipeline for neoantigen identification and validation, 09 November 2023, PREPRINT (Version 1) available at Research Square